

## Accepted Manuscript

Extended daily dialysis versus intermittent hemodialysis for acute kidney injury: A systematic review

Joana Briosa Neves, Filipe Brogueira Rodrigues, Mafalda Castelão, João Costa, José António Lopes

PII: S0883-9441(16)00053-8  
DOI: doi: [10.1016/j.jcrc.2016.02.001](https://doi.org/10.1016/j.jcrc.2016.02.001)  
Reference: YJCRC 52067

To appear in: *Journal of Critical Care*



Please cite this article as: Neves Joana Briosa, Rodrigues Filipe Brogueira, Castelão Mafalda, Costa João, Lopes José António, Extended daily dialysis versus intermittent hemodialysis for acute kidney injury: A systematic review, *Journal of Critical Care* (2016), doi: [10.1016/j.jcrc.2016.02.001](https://doi.org/10.1016/j.jcrc.2016.02.001)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Title**

Extended daily dialysis versus intermittent hemodialysis for acute kidney injury: a systematic review

**Authors**

Joana Briosa Neves<sup>1,2</sup>, Filipe Brogueira Rodrigues<sup>1,3,4</sup>, Mafalda Castelão<sup>3,4</sup>, João Costa<sup>3,4,5,6</sup>, José António Lopes<sup>2</sup>

**Institutional affiliation**

<sup>1</sup> Department of Medicine, Centro Hospitalar de Lisboa Norte, Portugal.

<sup>2</sup> Service of Nephrology and Renal Transplantation, Centro Hospitalar de Lisboa Norte, Portugal.

<sup>3</sup> Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal.

<sup>4</sup> Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal.

<sup>5</sup> Center for Evidence-Based Medicine, Faculty of Medicine, University of Lisbon, Portugal.

<sup>6</sup> Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Faculty of Medicine, University of Lisbon, Portugal.

**Corresponding author**

José António Lopes, PhD MD

Service of Nephrology and Renal Transplantation, Department of Medicine

Centro Hospitalar Lisboa Norte, EPE

Av. Prof. Egas Moniz

1649-035 Lisboa, Portugal

Telephone +351961203912; Fax +351217805679; Email: jalopes93@hotmail.com

### **Contributions**

JAL was the guarantor. All authors contributed to the drafting of the manuscript, the development of the selection criteria, the risk of bias assessment strategy, data extraction criteria, and result interpretation and discussion. FBR developed the search strategy. JBN, FBR and MC conducted the report screening, study inclusion, and data extraction. FBR e JC performed the statistical analysis. JAL and JC provided expertise on acute kidney injury and on methodology. All authors read, provided feedback and approved the final manuscript.

### **Support**

No financial or non-financial support of any kind was provided for this systematic review.

### **Disclosure**

The authors disclose no potential conflicts of interest.

### **Keywords**

Acute kidney injury, renal dialysis, systematic review

**Extended daily dialysis versus intermittent hemodialysis for acute kidney injury:  
a systematic review**

To the Editor:

Acute kidney injury (AKI) occurs frequently during hospitalization[1] and is associated with deleterious effects[2,3]. The need for renal replacement therapy (RRT) in AKI is rising[4] and continuous RRT (CRRT), extended daily dialysis (EDD) and intermittent hemodialysis (IHD) are the most commonly used techniques in developed countries. Previous systematic reviews and meta-analysis have analyzed the use of RRT in AKI but failed to prove major outcome differences between CRRT and intermittent techniques, such as EDD and IHD[5-7]. Hemodynamic stability and the needed rate of solute clearance guide the clinical decision regarding dialytic modalities in AKI and evidence supporting the choice between IHD or EDD is limited[7]. Therefore, we aimed to systematically review published data comparing the safety and efficacy of EDD and IHD in AKI.

The protocol for this systematic review was pre-registered at PROSPERO (CRD42015025034) and the authors followed PRISMA guidelines (Annex S1). MEDLINE, CENTRAL (Cochrane Library), and clinicaltrials.gov were searched (June 2015) for studies comparing EDD and IHD in adult patients with AKI. Two independent authors selected studies, extracted data and evaluated the risk of bias. Primary outcomes were renal function recovery and mortality at 90 days. Secondary outcomes were intensive care unit (ICU) and hospital length of stay, hemodynamic stability, in-hospital mortality, and mortality at 30 days.

After deduplication 2735 studies were screened for eligibility, eight underwent full-text review and two were included[8,9] (Figure S1 - PRISMA flow diagram).

Study characteristics, baseline characteristics of patients and reported outcomes are summarized on Tables 1, 2, and 3, respectively. Both studies have an overall moderate risk of bias: Kumar et al[8] due to selection bias and Khanal et al[9] due to confounding bias, selection bias, reporting bias, and bias due to baseline imbalances.

Kumar and colleagues[8] describe a quasi-randomized study including 30 patients equally divided between arms. The mean age was 37.8 years (standard deviation (SD) 13.4), and most patients were women (n=23, 76.7%). The most frequent cause of AKI was sepsis (including 13 (43.3%) cases of obstetric sepsis), followed by hypovolemia. Extremely ill patients were excluded, less than half (n=13, 43.3%) of patients exhibited dysfunction of two organs and only six (20%) required vasopressor use. At 90 days follow-up, all had recovered renal function and no deaths were reported. A non-significant trend towards a greater rate of intradialytic hypotension was observed for IHD. However, the blood flow rate in EDD was occasionally reduced to 200ml/min in response to vital sign changes. No data is provided for ICU or hospital length of stay, or intradialytic need to start or escalate vasopressors.

Khanal et al[9] describe a retrospective cohort study comparing the three most frequently used RRT in AKI, with 118 patients undergoing EDD and 20 IHD. The mean age was 57.7 years (SD 7.97), and most patients were men (n=81, 58.7%). Sepsis and surgery were the most frequent causes of AKI. Patients had high baseline illness severity, with elevated mean APACHE IV acute physiology score (108.62, SD 37.96) and SOFA scores (12.40, SD 4.70) and rate of vasopressor use (n=118, 85.5%). Of note, patients undergoing IHD had a lower baseline rate of vasopressor use when compared with EDD. Hazard ratios (IHD *versus* EDD) adjusted for baseline and time-varying characteristics were 1.22 (95%CI: 0.33-4.43) for in-hospital death

and 2.22 (95%CI: 0.49-10.11) for 90-day mortality. No data is provided for renal function recovery, mortality at 30 days, or for outcomes related to in-session hemodynamic stability.

The two studies have disparate study designs and report on widely different populations, which compromises data aggregation and comparisons. The study by Kumar is interventional and its patients are characteristic of an underdeveloped country (young, with high rates of obstetric sepsis, hipovolemia, and malaria as causes of AKI), while Khanal reports on a severely ill population from a developed country. Also, Kumar's small sample size and less ill patients may contribute to the excellent endpoints achieved (no deaths and all recovered renal function). Finally, Khanal and colleagues indicate that IHD patients were slightly less ill than the EDD ones but this effect may be limited by the baseline and time-varying modeled statistical analysis used.

This systematic review gathers very low-quality evidence (i.e., any estimate of effect is very uncertain[10]) suggesting that IHD may lead to greater intradialytic hemodynamic instability than EDD, and that both interventions may carry similar in-hospital and 90-day risks of death. In the authors' opinion, no strong recommendations can be made. Notwithstanding, one important result is the confirmation that the available data on this topic is very scarce: there are only two published studies, both with moderate risk of bias, suboptimal designs and sample sizes, and that missed to report all relevant outcomes. To drive patient care strong evidence is essential and this systematic review highlights the pressing need for studies comparing the safety and efficacy of EDD and IHD in AKI.

**References**

1. Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of AKI: a meta-analysis. *Clin J Am Soc Nephrol*. 2013;8(9):1482-1493.
2. Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis*. 2009;53(6):961-973.
3. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. *Kidney Int*. 2012;81(5):442-448.
4. Hsu RK, McCulloch CE, Dudley RA, Lo LJ, Hsu C. Temporal Changes in Incidence of Dialysis-Requiring AKI. *J Am Soc Nephrol*. 2013;24:37-42.
5. Rabindranath K, Adams J, Macleod AM, Muirhead N. Intermittent versus continuous renal replacement therapy for acute renal failure in adults. *Cochrane Database Syst Rev*. 2007(3):CD003773.
6. Zhang L, Yang J, Eastwood GM, Zhu G, Tanaka A, Bellomo R. Extended Daily Dialysis Versus Continuous Renal Replacement Therapy for Acute Kidney Injury: A Meta-analysis. *Am J Kidney Dis*. 2015.
7. Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M. Renal replacement therapy in patients with acute renal failure: a systematic review. *JAMA*. 2008;299(7):793-805.
8. Kumar N, Ahlawat RS. Extended daily dialysis in acute renal failure: a new therapeutic approach. *Iran J Kidney Dis*. 2007;1(2):63-72.
9. Khanal N, Marshall MR, Ma TM, Pridmore PJ, Williams AB, Rankin AP. Comparison of outcomes by modality for critically ill patients requiring renal

replacement therapy: a single-centre cohort study adjusting for time-varying illness severity and modality exposure. *Anaesth Intensive Care*.

2012;40(2):260-268.

10. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*.

2008;336(7650):924-926.

ACCEPTED MANUSCRIPT



**Tables**

Table 1 – Characteristics of included studies

Table 2 – Baseline characteristics of included patients

Table 3 – Reported outcomes of included studies

ACCEPTED MANUSCRIPT

Table 1 – Characteristics of included studies

Source	Study design	Study centers	Study period	Setting	Number of patients	Inclusion criteria	Definition of AKI	Definition of interventions	Reported causes of AKI	Follow-up	Outcomes
Kumar et al	Quasi-randomized interventional study	1; India	2005-2006	Hospital	30	>14 <60 years old AKI Absence of CKD Absence of >2 failing organs	Serum creatinine $\geq$ 2.0mg/dL or an increase in serum creatinine >50% over the baseline value	EDD: 8 hours per session, daily; IHD: 4 hours per session, thrice a week.	Obstetric sepsis (43.3%) Hypovolemia (36.7%) Malaria (10%) Other causes of sepsis (6.7%) Nephrotoxicity (3.3%)	90 days	In-hospital mortality Recovery of renal function
Khanal et al	Retrospective cohort study	1; New Zealand	2002-2008	Intensive care unit	138	>16 years old AKI or acute-on-chronic renal disease except if CKD on maintenance dialysis	RIFLE criteria	EDD: 8 to 10 hours per session, daily or on alternate days at physician discretion; IHD: 4 to 6 hours per session, daily or on alternate days at physician discretion.	Sepsis (69.6%) Postoperative (42%)	90 days	In-hospital mortality Mortality at 90 days

AKI: acute kidney injury; CKD: chronic kidney disease; EDD: extended daily dialysis; IHD: intermittent hemodialysis; RIFLE: Renal Injury Failure Loss, End-stage kidney disease

Table 2 – Baseline characteristics of included patients

	Kumar et al.		Khanal et al.	
	IHD	EDD	IHD	EDD
Number of patients	15	15	20	118
Age [mean (SD); years]	38.2 (12.2)	37.3 (15.0)	58.6 (17.6)	57.6 (4.9)
Male [n (%)]	4 (26.7)	3 (25.0)	11 (55)	70 (59.3)
Baseline eGFR [mean (SD); ml/min/1.73m <sup>2</sup> ]	N/A	N/A	59.8 (40.0)	59.5 (29.4)
Cause of AKI				
Sepsis [n (%)]	7 (46.7)	8 (53.3)	14 (70.0)	82 (69.5)
Postoperative [n (%)]	0 (0.0)	0 (0.0)	6 (30.0)	52 (44.1)
Nephrotoxicity [n (%)]	1 (6.7)	0 (0.0)	N/A	N/A
APACHE IV acute physiology score [mean (SD)]	N/A	N/A	100.7 (35.5)	108.9 (38.5)
APACHE IV risk of death in % [mean (SD)]	N/A	N/A	68.3 (26.2)	67.7 (28.2)
SOFA score [mean (SD)]	N/A	N/A	10.6 (4.4)	12.7 (4.7)
Organ dysfunction				
1 organ [n (%)]	9 (60.0)	8 (53.3)	N/A	N/A
2 organs [n (%)]	6 (40.0)	7 (46.7)	N/A	N/A
Need of mechanical ventilatory support [n (%)]	0 (0.0)	0 (0.0)	N/A	N/A
Hemodynamic stability before dialysis				
MAP [mean (min-max)]	103.3 (89.9-109.9)	101.9 (99.9-109)	N/A	N/A
Need of vasopressor drugs [n (%)]	3 (20.0)	3 (20.0)	15 (75.0)	103 (88.0)
Number of dialytic sessions	82	140	55	413

EDD: extended daily dialysis; IHD: intermittent hemodialysis; SD: standard deviation; N/A: not available; eGFR: estimated glomerular filtration rate; AKI: acute kidney injury; MAP: mean arterial pressure.

Table 3 – Reported outcomes of included studies

	Kumar et al			Khanal et al		
	IHD	EDD	Effect measure*	IHD	EDD	Effect measure*
Renal function recovery [n (%)]	15 (100)	15 (100)	RR 1.00 (0.88-1.13)	N/A	N/A	N/A
Mortality at 90 days [n (%)]	0 (0)	0 (0)	RR 1.00 (0.07-14.55)	N/A	N/A	HR 2.22 (0.49-10.11)
Days in ICU [mean (SD)]	N/A	N/A	N/A	11.2 (11.2)	10.1 (9.5)	MD 1.1 (-4.10-6.30)
In-session hemodynamic stability						
Hypotensive episodes [n (%)]	6 (7.3)	0 (0.0)	RR 13.00 (0.80-212.02)	N/A	N/A	N/A
Post-dialytic MAP [mean (min-max)]	73 (70-79)	78.6 (75-83)	Not estimable	N/A	N/A	N/A
In-hospital mortality [n (%)]	0 (0)	0 (0)	RR 1.00 (0.07-14.55)	N/A	N/A	HR 1.22 (0.33-4.43)
Mortality at 30 days [n (%)]	0 (0)	0 (0)	RR 1.00 (0.07-14.55)	N/A	N/A	N/A

EDD: extended daily dialysis; IHD: intermittent hemodialysis; RR: risk ratio (95% confidence interval); N/A: Not available; HR: hazard ratio (95% confidence interval); ICU: intensive care unit; SD: standard deviation; MD: mean difference (SD); MAP: mean arterial pressure; \*: IHD versus EDD